- Home
- VSTM vs RGNX Comparison
VSTM vs RGNX Comparison
Compare VSTM & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | RGNX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.8M | 678.3M |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VSTM | RGNX |
|---|---|---|
| Price | $7.26 | $15.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $13.38 | ★ $30.78 |
| AVG Volume (30 Days) | ★ 1.7M | 684.2K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $13,379,000.00 | ★ $161,318,000.00 |
| Revenue This Year | $208.54 | $132.80 |
| Revenue Next Year | $251.40 | $45.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 33.79 | ★ 91.30 |
| 52 Week Low | $4.01 | $5.04 |
| 52 Week High | $11.25 | $15.41 |
Technical Indicators
Market Signals| Indicator | VSTM | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 61.78 |
| Support Level | $6.68 | $12.87 |
| Resistance Level | $8.14 | $14.65 |
| Average True Range (ATR) | 0.57 | 0.95 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 25.45 | 77.13 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.